LEESGGGLVQPGGSMK acetate

Cat. No.: HY-P3149B

Molecular Formula: $C_{66}H_{112}N_{18}O_{26}S$

Molecular Weight: 1605.76

Sequence Shortening: LEESGGGLVQPGGSMK

Target: TNF Receptor

Pathway: Apoptosis

Storage: Sealed storage, away from moisture
Powder -80°C 2 years
-20°C 1 year
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

LEESGGGLVQPGGSMK (acetate)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 100 mg/mL (62.28 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.6228 mL	3.1138 mL	6.2276 mL
	5 mM	0.1246 mL	0.6228 mL	1.2455 mL
	10 mM	0.0623 mL	0.3114 mL	0.6228 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
Solubility: 100 mg/mL (62.28 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1].

In Vitro

The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Dorothée LEBERT, et al. A method for quantifying therapeutic antibodies. EP3371592A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA